Motor neuron disease (MND/ALS) — an Australian patient's guide

What is motor neuron disease?

Motor neuron disease (MND) is the term used in Australia to describe amyotrophic lateral sclerosis (ALS) and its variants — a group of conditions characterised by the progressive degeneration of upper motor neurones (nerve cells in the brain that transmit signals down the spinal cord) and lower motor neurones (nerve cells in the spinal cord and brainstem that connect to muscles). As these motor neurones are lost, the muscles they control gradually weaken.

MND does not affect sensation in most cases — pain, temperature, and touch typically remain intact until late. It does not usually affect bladder or bowel function early in its course. What it does affect, progressively and at different rates in different people, is the ability to move, speak, swallow, and eventually breathe.

According to MND Australia and the Australian MND Registry, approximately 2,000 Australians live with MND at any given time, with around 700 new diagnoses each year. Peak onset is between 50 and 70 years of age. Median survival from symptom onset is three to five years, though this is highly variable — some people live a decade or more, particularly those with primary lateral sclerosis (upper motor neurone predominant).

A. Core clinical — the AU general-practice framework

The subtypes

The MND umbrella covers several presentations (Hardiman Lancet 2017):

• Classic ALS (~80%): mixed upper and lower motor neurone involvement — the most common subtype
• Primary lateral sclerosis (PLS): upper motor neurone only; slowest progression; best prognosis
• Progressive muscular atrophy (PMA): lower motor neurone only; often mistaken for other neuromuscular conditions
• Progressive bulbar palsy (PBP): bulbar onset (speech and swallowing first affected); shortest median survival
• Flail arm / flail leg variants: predominantly proximal limb onset; intermediate survival

Genetics

Approximately 10% of MND is familial. The most common genetic cause worldwide, including in Australia, is C9orf72 hexanucleotide repeat expansion — the same mutation associated with frontotemporal dementia (Renton Neuron 2011). Other known gene mutations include SOD1, TARDBP (TDP-43), and FUS. Genetic testing is now part of the diagnostic workup for all people with MND in Australia, with implications for family members and access to specific treatments (tofersen for SOD1-ALS).

Cognitive and behavioural change

Approximately 50% of people with MND have measurable cognitive or behavioural changes. Around 15% meet criteria for frank ALS-frontotemporal dementia (ALS-FTD) — particularly those with C9orf72 mutations. Behavioural change (disinhibition, apathy, rigidity) may precede the motor syndrome. Cognitive capacity for decision-making, including advance care planning and voluntary assisted dying, requires formal assessment in this context.

B. Diagnosis — the GP’s recognition role

Warning signs that warrant urgent neurology referral

The Gold Coast criteria 2020 require progressive upper and lower motor neurone signs in at least two body regions. The GP’s role is pattern recognition and timely referral — not formal diagnosis.

Presentation features that raise suspicion:

• Asymmetric, painless, progressive limb weakness — foot drop, hand weakness, forearm wasting
• Mixed upper motor neurone signs (spasticity, brisk reflexes, extensor plantar response) with lower motor neurone signs (wasting, fasciculations, reduced reflexes) in the same limb or across regions
• Tongue fasciculations and wasting — a specific and important finding
• Bulbar features — dysarthria (slurred speech), dysphagia, excessive saliva, or pseudobulbar affect (emotional lability)
• Preserved sensation, sphincter function (early), and eye movements — these help distinguish MND from other conditions
• Unintentional weight loss with bulbar features
• Respiratory symptoms — breathlessness on exertion or lying flat, reduced ability to cough

Fasciculations (visible flickering of muscle under the skin) occur in many benign conditions, particularly in tired or caffeinated individuals, and alone are rarely significant. It is the combination with weakness and upper motor neurone signs that requires investigation.

What happens after referral

The neurologist orders electromyography and nerve conduction studies (EMG/NCS) to document lower motor neurone involvement across multiple body segments. MRI brain and cervical spine excludes structural mimics — most importantly cervical myelopathy from degenerative spine disease, which is common and can produce a similar mixed picture. Additional conditions to exclude include Kennedy disease (X-linked spinobulbar muscular atrophy), multifocal motor neuropathy with conduction block (MMN-CB), myasthenia gravis, and paraneoplastic syndromes.

Diagnosis often takes six to twelve months from first symptoms. Referral to a specialist MND clinic — where a multidisciplinary team assesses the patient comprehensively — accelerates diagnosis and initiates support planning early. Direct referral from the GP to an MND clinic (rather than generic neurology) is recommended.

C. Treatment in Australia

Disease-modifying therapies

Riluzole 50 mg twice daily is the longest-established disease-modifying treatment. It inhibits glutamate-mediated excitotoxicity. Three systematic reviews, including Miller et al. Cochrane 2012, confirm modest but statistically significant survival prolongation of approximately two to three months. It is PBS-funded under Authority Required for confirmed MND. Side effects include nausea, fatigue, and elevated liver enzymes — liver function monitoring is required.

Edaravone is a free-radical scavenger that modestly slows the rate of functional decline in a defined population — those with early disease, confirmed definite or probable ALS, and retained respiratory function (FVC ≥80%) — as shown in the Writing Group Lancet Neurology 2017 trial. It is PBS-funded under Authority Required and administered as IV infusions in hospital infusion units.

Tofersen — a SOD1-targeting antisense oligonucleotide administered intrathecally — received TGA registration and PBS Section 100 listing in 2024 following the VALOR trial (Miller NEJM 2022). It is indicated specifically for SOD1-gene-related MND. Genetic testing to confirm SOD1 mutation is prerequisite.

Sodium phenylbutyrate-taurursodiol (AMX0035 / Albrioza) is no longer available. Despite initial conditional FDA approval after the CENTAUR trial (Paganoni NEJM 2020), it was withdrawn by the FDA and TGA in 2024 after the larger phase III PHOENIX trial did not replicate the benefit.

Symptom management

Most MND management is symptom-focused, aiming to preserve function and quality of life as long as possible:

• Spasticity: baclofen, tizanidine, physical therapy
• Cramps: quinine sulfate (with monitoring), magnesium, stretching
• Excessive saliva: glycopyrrolate, hyoscine, botulinum toxin injection to parotid glands
• Pseudobulbar affect (pathological laughing and crying): SSRIs are effective; dextromethorphan-quinidine is used in some countries
• Pain: analgesics as clinically appropriate; neuropathic agents if applicable; palliative care input
• Depression and anxiety: extremely common; antidepressants and psychological support are appropriate

D. Australian operations — the multidisciplinary clinic

The most important structural intervention in MND care is attendance at a dedicated multidisciplinary MND clinic. Aridegbe et al. 2013 demonstrated that multidisciplinary clinic attendance improves both survival and quality of life.

MND clinics in Australia are available at major tertiary hospitals in each state. MND Australia maintains a directory. The team typically includes:

• Neurologist (diagnosis, disease-modifying treatment)
• Respiratory physician (FVC and SNIP monitoring, NIV initiation)
• Dietitian (nutrition monitoring, PEG planning)
• Speech and language pathologist (dysarthria, dysphagia, communication devices)
• Occupational therapist (home modification, adaptive equipment, driving)
• Physiotherapist (mobility, falls, respiratory exercises)
• Clinical neuropsychologist (cognitive assessment, FTD screen)
• Palliative care physician (symptom management, advance care planning)
• Social worker (NDIS navigation, carer support, financial planning)
• MND Australia coordinator (community liaison, equipment, peer support)
• Clinical geneticist (genetic testing, family counselling)

Respiratory care

Respiratory failure is the usual cause of death in MND. Regular monitoring with spirometry (FVC — forced vital capacity) and sniff inspiratory pressure (SNIP) identifies decline. Non-invasive ventilation (NIV, typically BiPAP) is initiated when symptomatic or when FVC falls below 50% predicted or SNIP below 40 cmH₂O. Bourke et al. Lancet Neurology 2006 demonstrated that NIV improves both survival and quality of life. Some people with bulbar MND have difficulty tolerating NIV — careful fitting and support are essential.

Nutrition and PEG

Gastrostomy (PEG or RIG) is planned early — before significant weight loss or respiratory compromise — when dysphagia is significant. The ProGas / Stavroulakis Lancet Neurology 2015 study informs the timing of PEG relative to respiratory function.

NDIS

MND qualifies for National Disability Insurance Scheme (NDIS) support. Early application is recommended, as MND progresses — funding can support home modifications, equipment, personal care, and carer respite. MND Australia provides NDIS navigation support.

E. Special populations and advance care planning

Voluntary assisted dying (VAD)

VAD is now lawful in all Australian states and the Northern Territory. MND is a terminal illness that qualifies in all jurisdictions. The process requires a voluntary, competent, and sustained request; assessment by two trained practitioners; and compliance with state law. Cognitive capacity must be specifically assessed given the risk of MND-related cognitive change. Advance care planning should begin early — well before capacity may be affected — and be revisited as the illness progresses. Your GP, neurologist, or palliative care physician can provide information about the process in your state or territory.

Carers and families

MND progressively shifts care responsibilities to family members and formal carers. Carer wellbeing, fatigue, and financial impact require proactive attention. Respite services, carer allowances, and psychological support are available through NDIS, Carer Gateway (1800 422 737), and MND Australia.

Young-onset MND

MND in people under 45 years is less common but not rare. Familial genetics (C9orf72, SOD1, FUS) are proportionally more relevant in younger-onset cases. Fertility, employment, children, and long-term financial planning are additional considerations requiring early discussion.

When to escalate

Refer to neurology urgently when MND is suspected:

• Mixed UMN and LMN signs in the same limb or across regions, particularly with fasciculations
• Tongue wasting or fasciculation
• Bulbar symptoms with limb weakness
• FVC declining rapidly — respiratory physician co-management needed
• Unintentional weight loss with dysphagia

Contact emergency services or present to hospital when:

• Acute respiratory failure or breathlessness at rest
• Inability to swallow with aspiration risk
• Unexplained acute deterioration (exclude intercurrent infection, which can temporarily worsen MND symptoms substantially)

What this article is and is not

This is general health information drawn from MND Australia, Hardiman Lancet 2017, Brown NEJM 2017, Shefner Gold Coast criteria 2020, Miller Cochrane 2012, and the Bourke NIV trial 2006. It is not personal medical advice and does not create a doctor–patient relationship. MND management requires specialist neurology and multidisciplinary team input. Treatment options and PBS listings evolve — verify current availability with your treating team.

For Australian resources: MND Australia, HealthDirect — Motor neuron disease, Better Health Channel.

For urgent support: Lifeline 13 11 14 · MND Australia national support 1800 777 175

---

Sources cited

1. MND Australia
2. Australian MND Registry
3. Hardiman O et al. — ALS (Lancet 2017)
4. Brown RH, Al-Chalabi A — ALS review (NEJM 2017)
5. Shefner JM et al. — Gold Coast criteria (Clin Neurophysiol 2020)
6. Renton AE et al. — C9orf72 hexanucleotide repeat expansion (Neuron 2011)
7. Miller RG et al. — Riluzole for ALS (Cochrane 2012)
8. Writing Group — Edaravone in ALS (Lancet Neurology 2017)
9. Miller TM et al. — Tofersen for SOD1-ALS (NEJM 2022)
10. Paganoni S et al. — AMX0035 / CENTAUR trial (NEJM 2020)
11. Bourke SC et al. — NIV in MND (Lancet Neurology 2006)
12. Aridegbe T et al. — Multidisciplinary MND clinic and survival (Amyotroph Lateral Scler 2013)
13. Stavroulakis T et al. — ProGas study: PEG in ALS (Lancet Neurology 2015)
14. HealthDirect — Motor neuron disease
15. Better Health Channel — Motor neurone disease